Global Drug Facility adds new TB drug to its catalogue

The Global Drug Facility, which provides tuberculosis (TB) treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

J&J invests $500m into global HIV and TB treatment

10 October 2019 Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

Big Pharma

US considers shortening marketing exclusivity to push forward USMCA

3 December 2019 The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.

Big Pharma

TAG supports opposition of Sanofi TB drug patents in India

9 December 2019 Treatment Action Group, a US-based organisation focused on research of diseases such as HIV/AIDS and tuberculosis, has applauded an opposition that aims to block Sanofi from patenting a new TB drug in India.

More on this story

Big Pharma

J&J invests $500m into global HIV and TB treatment

10 October 2019 Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

Big Pharma

US considers shortening marketing exclusivity to push forward USMCA

3 December 2019 The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.

Big Pharma

TAG supports opposition of Sanofi TB drug patents in India

More on this story

Big Pharma

J&J invests $500m into global HIV and TB treatment

10 October 2019 Johnson & Johnson has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis across the world by 2030.

Big Pharma

US considers shortening marketing exclusivity to push forward USMCA

3 December 2019 The Trump administration is considering shortening the period that big pharma companies’ biologic drugs are protected by marketing exclusivity from biosimilar competition.

Big Pharma

TAG supports opposition of Sanofi TB drug patents in India